Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity.

Rocca C, Scavello F, Colombo B, Gasparri AM, Dallatomasina A, Granieri MC, Amelio D, Pasqua T, Cerra MC, Tota B, Corti A, Angelone T.

FASEB J. 2019 Jun;33(6):7734-7747. doi: 10.1096/fj.201802707R. Epub 2019 Apr 11.

PMID:
30973759
2.

Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement.

Dallatomasina A, Gasparri AM, Colombo B, Sacchi A, Bianco M, Daniele T, Esposito A, Pastorino F, Ponzoni M, Marcucci F, Curnis F, Corti A.

Cancer Res. 2019 Apr 15;79(8):1925-1937. doi: 10.1158/0008-5472.CAN-18-0289. Epub 2019 Feb 22.

PMID:
30796053
3.

Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis.

Maugeri N, Capobianco A, Rovere-Querini P, Ramirez GA, Tombetti E, Valle PD, Monno A, D'Alberti V, Gasparri AM, Franchini S, D'Angelo A, Bianchi ME, Manfredi AA.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaao3089. doi: 10.1126/scitranslmed.aao3089.

PMID:
30045975
4.

Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Corti A, Gasparri AM, Ghitti M, Sacchi A, Sudati F, Fiocchi M, Buttiglione V, Perani L, Gori A, Valtorta S, Moresco RM, Pastorino F, Ponzoni M, Musco G, Curnis F.

Adv Funct Mater. 2017 Sep 26;27(36). pii: 1701245. doi: 10.1002/adfm.201701245.

5.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

6.

A new chromogranin A-dependent angiogenic switch activated by thrombin.

Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A.

Blood. 2013 Jan 10;121(2):392-402. doi: 10.1182/blood-2012-05-430314. Epub 2012 Nov 27.

7.

Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice.

Curnis F, Gasparri AM, Longhi R, Colombo B, D'Alessio S, Pastorino F, Ponzoni M, Corti A.

Cell Mol Life Sci. 2012 Aug;69(16):2791-803. doi: 10.1007/s00018-012-0955-z. Epub 2012 Mar 14.

PMID:
22415324
8.

Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.

Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A.

Cancer Res. 2011 Sep 1;71(17):5881-90. doi: 10.1158/0008-5472.CAN-11-1273. Epub 2011 Jul 28.

9.

Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A.

J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11.

10.

Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.

Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A.

Mol Cancer Ther. 2008 Dec;7(12):3859-66. doi: 10.1158/1535-7163.MCT-08-0538.

11.

Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.

Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P.

Cancer Res. 1999 Jun 1;59(11):2650-6.

12.

Production of mouse monoclonal antibodies directed against the oolemma of human and hamster oocytes by intra-splenic injection of oocytes.

Fusi FM, Gasparri AM, Pelagi M, De Santis CT, Grieco SE, Siccardi AG, Ferrari A.

Am J Reprod Immunol. 1995 Jan;33(1):122-30.

PMID:
7619226

Supplemental Content

Loading ...
Support Center